• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 84-98 of 180 results

2028 Exhibit: Jt Claim Const Charts

Document IPR2015-01117, No. 2028 Exhibit - Jt Claim Const Charts (P.T.A.B. Mar. 28, 2016)
Page 1 of 14 Owner Ex. 2028 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 2 of 14 Owner Ex. 2028 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 3 of 14 Owner Ex. 2028 Par Pharm. v. Horizon IPR2015-01117,-01127
cite Cite Document

2013 Exhibit: Berry 2001

Document IPR2015-01117, No. 2013-2 Exhibit - Berry 2001 (P.T.A.B. Mar. 28, 2016)
(J Pediatr 2001;138:S56-S61) The long-term treatment of patients with urea cycle disorders involves the use of a low-protein diet, supplementa- tion with certain amino acids, and ad- ministration of organic compounds to augment waste nitrogen excretion.1-8 Optimal care, however, necessitates the use of a comprehensive long-term management program that anticipates From the Divisions of Human Genetics and Molecular Biology and Endocrinology and Diabetes, Department of Pediatrics, University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Pennsylvania, and the Metabolic Clinic, Child Develop- ment and Rehabilitation Center, Doernbecher Chil- dren’s Hospital, Oregon Health Sciences University, Portland, Oregon.
The treatment must be tailored to the needs of the patient as reflected in the growth rate, plasma ammonia, and amino acid lev- els and ancillary tests such as blood counts and serum albumin.
These include poor growth, developmental delay, learning problems, speech disor- der, attention deficit hyperactivity dis- order, mental retardation, spasticity as in cerebral palsy, seizure disorder, and hepatomegaly with and without liver function test abnormalities.1,2,13,14 It is important to note that normal variant short stature such as genetic short stature and constitutional delay of growth and puberty may also occur in patients with UCDs.
After the hyperammonemia is cor- rected or the disease process is stabi- lized, all of the sequelae such as learning problems, speech defect, cere- bral palsy, and seizure disorders will need to be treated, as with any child without a UCD.
Parents are to be instructed in the signs and symptoms of hyperam- monemia such as anorexia, vomiting, al- tered behavior, headache, visual distur- bances, ataxia, lethargy, and seizures that may indicate acute hyperammone- mia.
cite Cite Document

2025 Exhibit: Buphenyl Prescribing Info

Document IPR2015-01117, No. 2025 Exhibit - Buphenyl Prescribing Info (P.T.A.B. Mar. 28, 2016)
Page 1 of 9 Owner Ex. 2025 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 2 of 9 Owner Ex. 2025 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 3 of 9 Owner Ex. 2025 Par Pharm. v. Horizon IPR2015-01117,-01127
cite Cite Document

2016 Exhibit: Endo 2004

Document IPR2015-01117, No. 2016 Exhibit - Endo 2004 (P.T.A.B. Mar. 28, 2016)
Page 1 of 5 Owner Ex. 2016 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 2 of 5 Owner Ex. 2016 Par Pharm. v. Horizon IPR2015-01117,-01127 Page 3 of 5 Owner Ex. 2016 Par Pharm. v. Horizon IPR2015-01117,-01127
cite Cite Document

2014 Exhibit: Summar 2005

Document IPR2015-01117, No. 2014 Exhibit - Summar 2005 (P.T.A.B. Mar. 28, 2016)

cite Cite Document

2013 Exhibit: Expunged

Document IPR2015-01117, No. 2013 Exhibit - Expunged (P.T.A.B. Mar. 28, 2016)

cite Cite Document

2011 Exhibit: Maestri 1992

Document IPR2015-01117, No. 2011 Exhibit - Maestri 1992 (P.T.A.B. Mar. 28, 2016)
Page 1 of 3 Owner Ex. 2011 Par Pharm. v. Horizon IPR2015-01117 Page 2 of 3 Owner Ex. 2011 Par Pharm. v. Horizon IPR2015-01117 Page 3 of 3 Owner Ex. 2011 Par Pharm. v. Horizon IPR2015-01117
cite Cite Document

2023 Exhibit: UCDCG Consensus Statement

Document IPR2015-01117, No. 2023 Exhibit - UCDCG Consensus Statement (P.T.A.B. Mar. 28, 2016)

cite Cite Document

1023 Exhibit: Piscitelli

Document IPR2016-00283, No. 1023 Exhibit - Piscitelli (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1001 Exhibit: US Patent No 8,642,012

Document IPR2016-00283, No. 1001 Exhibit - US Patent No 8,642,012 (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1017 Exhibit: Shiple

Document IPR2016-00283, No. 1017 Exhibit - Shiple (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1021 Exhibit: Prosecution History of the 012 patent

Document IPR2016-00283, No. 1021-4 Exhibit - Prosecution History of the 012 patent (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1002 Exhibit: Declaration of Dr Neal Sondheimer

Document IPR2016-00283, No. 1002 Exhibit - Declaration of Dr Neal Sondheimer (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1026 Exhibit: US Patent No 5,968,979

Document IPR2016-00283, No. 1026 Exhibit - US Patent No 5,968,979 (P.T.A.B. Dec. 4, 2015)

cite Cite Document

1021 Exhibit: Prosecution History of the 012 patent

Document IPR2016-00283, No. 1021-3 Exhibit - Prosecution History of the 012 patent (P.T.A.B. Dec. 4, 2015)

cite Cite Document
<< 1 2 3 4 5 6 7 8 9 10 11 12 13 >>